Gradalis Announces Development of Clinically Relevant Exome Sequencing Bioinformatics Pipeline to Determine Clonal Tumor Mutation Burden
Optimal therapeutic targeting of cancer involves clonal signals which are expressed within all cancer cellsGradalis applies a novel clinically ...
manilatimes2d
Gradalis Announces Development of Clinically Relevant Exome Sequencing Bioinformatics Pipeline to Determine Clonal Tumor Mutation Burden
The paper details the methods and validation of Gradalis' exome sequencing procedure and associated bioinformatics ... which are sequenced on Illumina sequencers to a high coverage depth (930x tumor, ...
NewsBytes6d
China's reciprocal tariffs on US goods are now in effect
China 's tariffs of up to 15% on US farm goods have come into effect today. They hit a range of commodities from beef and ...
Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban
Beijing banned imports of Illumina’s gene-sequencing machines in response to U.S. tariffs.
Illumina to cut $100M in costs to cope with China ban
The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.
Fierce Biotech4d
Illumina aims to cut $100M in costs following China import ban
Illumina will seek to cut $100 million in expenses by the end of this fiscal year as it plans to deal with a loss of revenue ...
Illumina lowers outlook due to China sales ban, to cut $100 million in costs
Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced a ban ...
Illumina sees 2025 EPS of $4.50 after China ban, consensus $4.51
Illumina (ILMN) responded to the March 4 notice from the China Ministry of Commerce that the company is not permitted to export sequencing ...
JD Supra1d
The Illumina Ban and What It Means for Life Science Companies
Amid increasing economic tensions with the United States, China recently announced that it would ban Illumina, a U.S.-based company and the ...